HRS 9057
Alternative Names: HRS-9057Latest Information Update: 22 Jul 2024
At a glance
- Originator Shanghai Hengrui Pharmaceutical
- Class Heart failure therapies
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Autosomal dominant polycystic kidney disease; Cardiac oedema
Most Recent Events
- 01 Jul 2024 Shanghai Hengrui Pharmaceutical plans a phase I trial for Cardia oedema in China (Injection) (CTR20242367) NCT06506994)